AlphaQuest LLC Purchases New Stake in Aura Biosciences, Inc. (NASDAQ:AURA)

AlphaQuest LLC purchased a new stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 16,511 shares of the company’s stock, valued at approximately $136,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in Aura Biosciences by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after buying an additional 3,612 shares during the last quarter. State Street Corp grew its stake in shares of Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after purchasing an additional 26,841 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Aura Biosciences in the third quarter worth $1,037,000. Barclays PLC grew its stake in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Aura Biosciences by 4.1% in the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after purchasing an additional 39,379 shares in the last quarter. 96.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Aura Biosciences presently has an average rating of “Buy” and an average target price of $23.00.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 23,045 shares of company stock valued at $177,242 over the last three months. Company insiders own 5.40% of the company’s stock.

Aura Biosciences Stock Up 2.6 %

Shares of AURA stock opened at $7.54 on Tuesday. The stock has a 50-day simple moving average of $7.69 and a 200 day simple moving average of $8.68. The stock has a market capitalization of $376.63 million, a P/E ratio of -4.36 and a beta of 0.30. Aura Biosciences, Inc. has a fifty-two week low of $6.63 and a fifty-two week high of $12.38.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.